Tuberculosis (TB) continues to be the world's most important infectious cause of morbidity and mortality among adults. Nearly 9 million people develop TB disease each year, and an estimated 1.6 million die from the disease. Despite this enormous global burden, case detection rates are low, posing serious hurdles for TB control. Conventional TB diagnosis continues to rely on antiquated tests such as sputum smear microscopy, culture, tuberculin skin test, and chest radiography. These tests have several limitations and perform poorly in populations affected by the HIV epidemic. Conventional tests for detection of drug resistance are time consuming, tedious, and inaccessible in most settings. In this review, we describe recent advances in the diagnosis of latent and active TB, and detection of drug resistance. Although the perfect test will not be ready for large-scale rollout and integration into routine TB care services for some time, substantial progress has been made in expanding the TB diagnostic product pipeline. With the resurgence of interest in the development of new tools for TB control, and the recent influx of funding and political support, it is likely that the next few years will see the introduction of new diagnostic tools into routine TB control programs.
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It is estimated that approximately half of all patients with TB are still not diagnosed and appropriately treated. Each year, 1.6 million deaths occur due to TB. The problem is significantly worsened by HIV infection and the increasing prevalence of multidrug resistant (MDR) and extensively drug resistant (XDR) TB.
Conventional TB diagnosis continues to rely on sputum smear microscopy, culture, tuberculin skin test, and chest radiography. These tests have been used for nearly a century and have several limitations. Existing tools may be insufficient to control TB in developing countries, especially in countries ravaged by the HIV epidemic. 2 Hence there is an urgent need for newer or improved methods for diagnosis to accelerate the fight against TB and to meet the target of elimination by 2050. A recent modeling study showed that a rapid and universally accessible test that is not affected by HIV status, with a sensitivity of 85% for smear-positive and smear-negative cases, and a specificity of 97% can save an estimated 392,000 adjusted lives annually, or 22% of the global TB deaths.
The involvement of agencies such as the Stop TB Partnership's Working Group on New Diagnostics, the World Health Organization (WHO), the Special Program for Research and Training in Tropical Diseases (TDR), and the Foundation for Innovative New Diagnostics (FIND) has led to a resurgence of interest in the development of new TB diagnostics. Indeed, the development of new tools is a key component of the Global Plan to Stop TB, 2006 -2015 , the new global Stop TB Strategy. 4, 5 With the anticipated launch of new tools within the next few years, the Stop TB Partnership has recently established a Retooling Task Force to develop a framework for catalyzing policy makers and practitioners at global and national levels toward accelerated introduction of new tools into TB control programs. 6 In the past few years, the TB diagnostics pipeline has rapidly expanded. 2, [7] [8] [9] The current pipeline of products, together with their current stage of development, has been comprehensively described by Perkins and Cunningham (Table 1) .
2 Figure 1 illustrates the types of technology platforms that are currently in the pipeline. The technologies range from simple microscopic and growth detection systems to sophisticated molecular and immune-based systems. In this review, we describe recent advances in latent and active TB diagnosis, and progress made in the development of new tools for the diagnosis of MDR-TB.
ADVANCES IN LATENT TB DIAGNOSIS

Interferon-Gamma Release Assays
Until recently, the diagnosis of latent TB infection (LTBI) depended solely on the tuberculin skin test (TST), an imperfect test with known limitations. The biggest advance in recent times has been the development of T cell-based interferon-gamma release assays (IGRAs). IGRAs are in vitro blood tests that are based on interferon-gamma release after stimulation by TB-specific antigens (e.g., ESAT-6 and CFP-10). Two IGRAs are now commercially available-the Quanti-FERON-TB Gold In-Tube Assay (Cellestis Ltd, Carnegie, Victoria, Australia), and the T-SPOT.TB assay (Oxford Immunotec Limited, Abingdon, Oxon, UK).
As reviewed recently, IGRAs have very high specificity and are unaffected by prior bacille CalmetteGuérin (BCG) vaccination or sensitization to nontuberculous mycobacteria. 10, 11 The sensitivity of IGRAs in active TB is 75% to 90%, and there are data that suggest that IGRAs may be more sensitive than the TST in immunocompromised populations. Table 2 is a comparison of the performance and operational characteristics of the TST and IGRAs.
Overall, IGRAs are useful tests for the detection of LTBI, and their use is rapidly expanding in lowincidence countries. 11 However, IGRAs cannot distinguish between latent and active TB. Furthermore, data are lacking in children and HIV-infected and immunocompromised populations, and there are limited data on the ability of IGRAs to predict future development of TB disease. 12 Although IGRAs cannot replace conventional tests for active TB, they may have some potential to assist in the diagnosis of active TB in some settings, among selected populations such as young children, immunocompromised persons, and individuals with smear-negative and extrapulmonary disease. In these populations, microbiological diagnosis is often hard to establish, and IGRAs may offer supporting evidence to help establish a diagnosis of active TB.
The scope and role of IGRAs in developing countries remain unclear. 12 Several field evaluation projects are ongoing, and these studies should provide strong evidence for making policies for high-burden countries. 13 
A Specific Tuberculin Skin Test
A known limitation of the conventional TST is the lack of specificity of the purified protein derivative (PPD), a crude antigen mixture. An obvious solution to this problem is to replace PPD with antigens that are specific to Mycobacterium tuberculosis. This is the principle underlying an improved, specific skin test developed by the Statens Serum Institut, Copenhagen, Denmark. A recent randomized phase I clinical trial evaluated the safety of intradermal recombinant dimer ESAT-6 (rdESAT-6) compared with PPD and to determine the optimum dose range.
14 This pilot phase I study of safety, feasibility, and dose finding of intradermal rdESAT-6 provided proof of principle of a specific skin test for human use. No serious adverse events were observed but the study was not sufficiently powered to demonstrate complete safety. Further work is ongoing to improve this novel skin test and to include other specific TB antigens such as CFP-10. 14 
ADVANCES IN ACTIVE TB AND MDR/XDR-TB DIAGNOSIS
Improved (Optimized) Smear Microscopy Although much work is being done to develop new diagnostics, in most resource-limited countries, sputum smear microscopy remains the primary means for bacteriologic diagnosis of TB. Given the known limitations of smear microscopy, considerable research has been done to identify methods that can increase the sensitivity and optimize the yield of smear microscopy. 15 A series of recent systematic reviews has shown that microscopy can be optimized using at least three different approaches: chemical and physical processing (e.g., bleach) and concentration of sputum (e.g., centrifugation), fluorescence microscopy, and the examination of two (not three) sputum specimens. [16] [17] [18] The World Health Organization (WHO) recently revised its policies on smear microscopy. It now recommends the number of specimens to be examined for screening of TB cases can be reduced from three to two, in places where a well-functioning external quality assurance system exists, where the workload is very high and human resources are limited.
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Given the enhanced sensitivity of fluorescence microscopy (FM), work is also ongoing to develop simpler, field-friendly FM technology. Recently, it has been shown that low-cost ultrabright light-emitting diodes (LEDs) with a long lifespan could be a good replacement of expensive lamps used in conventional FM. Recent, emerging data suggest that LEDs show good excitation of auramine and other fluorescent dyes. 20 These LEDs have an expected bulb life of 15,000 hours in comparison with 200 hours for a conventional mercury bulb. Power consumption is lower, and battery operation is feasible. Thus the development of low-power, high-efficiency LEDs enables the development of microscopy systems that are substantially less expensive than conventional FM equipment, opening the door for widespread use of LED-based FM in developing countries. In view of these potential advantages, FIND has partnered with Carl Zeiss MicroImaging GmbH (Oberkochen, Germany) to develop an inexpensive, robust LED microscope for routine use in high-burden countries. 21 The microscope is configured for both white light and fluorescence applications and will allow switching between the two. Low power consumption will permit operation with a rechargeable battery built into the system. White light applications, using a mirror in settings of no electrical power, will also be possible. Preliminary data suggest that LED microscopy is feasible and slightly more sensitive than standard FM. 22 Field evaluation projects are currently ongoing in several countries.
Automated Liquid Cultures
Although mycobacterial culture is highly sensitive, it is not widely available in most developing countries. Also, solid culture [e.g., Löwenstein-Jensen (LJ)] is slow and results are often not available for weeks. Expanding culture capacity is urgently needed to address challenges posed by the epidemics of HIV-associated TB and drug resistant TB, especially in resource-limited settings. Liquid culture systems such as BACTEC and MGIT (Becton Dickinson, Sparks, MD) reduce the delays in obtaining results to days rather than weeks. 23 For drug susceptibility testing (DST), the delay may be reduced to as little as 10 days, compared with 28 to 42 days with conventional solid media. Liquid systems are more sensitive for detection of mycobacteria and may increase the case yield by 10% over solid media. 23 With increased sensitivity and reduced delays, liquid systems may contribute significantly to improved patient management. Liquid systems are, however, more prone to contamination. In addition, they are expensive and require expertise and infrastructure.
Recently, the WHO released a policy statement on the use of liquid culture systems. The WHO policy recommends phased implementation of these systems as part of a country-specific comprehensive plan for laboratory capacity strengthening, and addresses key issues, including biosafety, customer support, staff training, maintenance of infrastructure and equipment, specimen transport, and reporting of results. 24 
MODS
The microscopic-observation drug-susceptibility (MODS) assay for the detection of TB and MDR-TB, directly from sputum, relies on 3 principles: 1) M. tuberculosis grows faster in liquid medium than in solid medium; 2) characteristic cord formation can be visualized microscopically (''strings and tangles'' appearance) in liquid medium at an early stage; and 3) the incorporation of drugs permits rapid and direct DST concomitantly with the detection of bacterial growth. 25 MODS uses an inverted light microscope and Middlebrook 7H9 broth culture to rapidly detect early growth of M. tuberculosis of bacterial cells in the broth medium with or without antimicrobial drugs (for DST). In a recent large study in Peru, sensitivity of detection was 97.8% for MODS culture, 89.0% for automated mycobacterial culture, and 84.0% for LJ culture (p < 0.001); the median time to culture positivity was 7 days, 13 days, and 26 days, respectively (p < 0.001), and the median time to the results of susceptibility tests was 7 days, 22 days, and 68 days, respectively. 25 Thus MODS has excellent accuracy in field conditions and requires only an inverted light microscope. The cost of MODS culture has been estimated to be substantially lower than the cost of LJ culture and DST and that of automated mycobacterial culture. However, labor costs may be higher for MODS culture. 25 Nucleic Acid Amplification Tests Nucleic acid amplification tests (NAATs) have been evaluated for TB diagnosis and detection of drug resistance for nearly 2 decades. Several meta-analyses have shown that NAATs have high specificity for TB diagnosis, but modest and variable sensitivity, particularly in smear-negative TB and extrapulmonary disease. [26] [27] [28] [29] [30] [31] [32] Also, they are expensive and require special infrastructure and expertise. Considerable effort has been made to develop advanced versions of NAATs with better performance and operating characteristics. These include assays such as loop-mediated isothermal amplification (LAMP), Xpert MTB (Cepheid, Sunnyvale, California, USA), and the GenoType MTBDRplus assay (Hain Lifescience GmbH, Nehren, Germany).
Recently, LAMP was developed by scientists at Eiken Chemical Co. in Japan, which has characteristics that could enable the development of a simple, rapid, and sensitive detection test for TB and potentially other diseases. 33 FIND and Eiken have developed a TB detection assay that pairs simple manual specimen processing steps with LAMP, an isothermal amplification system that generates large amounts of target DNA in real time and results in visible amplification readout, with no need for instrumentation, probing, or opening the reaction tube to determine the result. Preliminary data on a multicenter evaluation of a first version of this assay were published in 2007 and showed the feasibility of performing the assay without sophisticated training or equipment. In that study, LAMP significantly outperformed microscopy. Sensitivity of LAMP in smear-and culture-positive sputum specimens was 97.7%; specificity in culture-negative samples was 99%. 33 The current version of the assay requires no equipment other than a heat block and utilizes reagents that are stable without a cold chain. Further refinements in the LAMP assay have been made, and further evaluation and field demonstration projects are under way.
Existing NAATs for TB are complicated because of the need for three separate steps for (1) specimen processing and nucleic acid extraction, (2) nucleic acid amplification, and (3) detection of amplified products. By combining these three steps into a single, automated process, the GeneXpert microfluidic and molecular testing platform developed by Cepheid, Inc. (Sunnyvale, CA) attempts to overcome these known limitations. 34 A specially designed cartridge allows all specimen processing steps to be performed in an automated manner by a single device that also performs real-time polymerase chain reaction (PCR) and sequence-specific detection of target amplicons. The Xpert MTB test being developed uses molecular beacons and six-color fluorescence detection for realtime identification of both M. tuberculosis and rifampin resistance in less than 120 minutes. Feasibility studies performed in Peru and Latvia have confirmed the assay's ease of use and its utility for desktop detection of MDR-TB (Catharina Boehme, FIND, pers. comm.). Larger field trials are under way.
With the emergence of XDR-TB, considerable attention has been focused on the rapid diagnosis of drug resistance. Molecular assays detect gene mutations that identify drug resistance. Among the molecular assays, line probe assays have shown great promise. 35 Line-probe assays are a family of novel DNA strip-based tests that use PCR and reverse hybridization methods for the rapid detection of mutations associated with drug resistance. Commercially available line-probe assays include the INNO-LiPA Rif. TB kit (Innogenetics NV, Gent, Belgium) and the GenoType MTBDRplus assay (Hain Lifescience GmbH, Nehren, Germany). A recent laboratory evaluation study from South Africa estimated the accuracy of the GenoType MTBDRplus assay performed directly on AFB smear-positive sputum specimens. Compared with conventional DST, the sensitivity, specificity, positive, and negative predictive values were 98.9%, 99.4%, 97.9%, and 99.7% for detection of rifampicin resistance; 94.2%, 99.7%, 99.1%, and 97.9% for detection of isoniazid resistance; and 98.8%, 100%, 100%, and 99.7% for detection of multidrug resistance compared with conventional results. 36 With overall performance characteristics that are superior to conventional culture and DST and the possibility for high throughput with substantial cost savings, these molecular tests may revolutionize MDR-TB diagnosis.
In June 2008, WHO announced a new policy statement endorsing the use of line probe assays for rapid screening of patients at risk of MDR-TB. The recommended use of line probe assays is currently limited to culture isolates and direct testing of smear-positive sputum specimens. Line probe assays are not recommended as a complete replacement for conventional culture and drug susceptibility testing.
However, the diagnosis of XDR-TB continues to be a challenge, especially because it requires additional data on resistance to several second-line drugs. Second-line drug resistance testing is poorly standardized, and gene mutations for second-line drugs are not well recognized.
Antibody Detection (Serological) Tests
Although no guideline recommends the use of serological (i.e., antibody-detection) tests, dozens of commercial kits are sold, mostly in developing countries. 37 Two recent systematic reviews have synthesized the available evidence on serological tests for TB. 38, 39 The evidence suggests that, at this point in time, published data on commercial serological tests for both pulmonary and extrapulmonary TB produce inconsistent estimates of sensitivity and specificity. For pulmonary TB, there was insufficient evidence to determine the accuracy of most commercial tests in smear microscopy-negative patients and none of the assays performed well enough to replace smear microscopy. 39 For extrapulmonary TB, there were no studies of commercial tests of sufficient quality to enable their evaluation in patients with HIV infection or in children because the tests could be potentially helpful in these groups. 38 Thus, at the present time, serological tests have little or no role to play in the diagnosis of TB.
Work is under way to develop improved versions of serological tests. Based on all the previous research, it seems unlikely that a single antigen will accurately detect TB. Rather, it is expected that several antigens, when used in combination, might generate an antibody profile or pattern that could be used to detect TB. This has been attempted with nonhuman primates with some success. 40 If successful, this approach could pave the way for a point-of-care (POC) product in a strip test format for detection of specific anti-TB antibodies in whole blood (or other clinical specimens) with performance adequate for use at the primary care level. At this stage, it is unclear if such POC tests can be successfully developed for clinical use, especially in populations where TB/ HIV coinfection is a concern. However, a better understanding of TB-specific biomarkers, and the application of new approaches such as metabolomics, genomics, and proteomics may facilitate the development of the much needed rapid POC test.
Antigen Detection Tests
The detection of TB antigens is an exciting new development. Unlike antibody detection, antigen detection offers the possibility of high specificity and correlation with bacterial burden. Although antibody detection assays are significantly impaired by immunosuppression, antigen detection assays should not be adversely impacted. Promising early attempts to detect M. tuberculosis antigens in sputum, serum, and urine have been reported. For example, lipoarabinomannan (LAM), a heat-stable glycolipid, has been found in the urine of 75 to 80% of culture-confirmed TB cases in studies from Tanzania and Ethiopia. 41, 42 Based on these early data, a prototype urinary LAM detection test was produced by Chemogen, Inc. (Portland, ME). A commercial version of this test is now marketed as the Clearview TB ELISA (Inverness Medical Innovations, Inc., Scarborough, ME). Large-scale field demonstration projects are currently ongoing.
Other Technologies under Development or Evaluation
In addition to the tests already described, there are several other technologies being developed or evaluated for TB, including detection of volatile organic compounds in the breath, electronic nose analysis of exhaled air, bacteriophage-based systems, skin patch test, colorimetric rapid culture systems, transrenal DNA detection, thin-layer cultures, and molecular beacons. These technologies have been reviewed elsewhere. 2, 8, 9, [43] [44] [45] [46] CONCLUSIONS After decades of little or no growth, the TB diagnostics pipeline has rapidly grown, with several technologies showing great promise. Clearly, this is evidence that good progress has been made in the development of new tests for TB. With the resurgence of interest in the development of new tools for TB control, and the recent influx of funding and political support, it is likely that the next few years will see the introduction of new tools into routine TB control programs. It is, however, important to ensure that policies on TB diagnostics are evidencebased. 43 Improvement and dissemination of new tools should have a profound effect on TB control throughout the world.
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